Clinical pharmacology of aminocaproic and tranexamic acids

Nilsson, I. M.

doi:10.1136/jcp.s3-14.1.41

Cited by 99 publications

(104 citation statements)

References 10 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…Additionally, all patients had undergone an ophthalmologic examination for acuity of vision, color vision, retina and field of vision. The eye exam was performed based on recommendations by literature and the German summary of product characteristics, as retinal changes had been observed in dogs after long-term treatment with high doses of tranexamic acid [11].…”

Section: Recruitment Of Participantsmentioning

confidence: 99%

Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study

Geisthoff

Seyfert

Kübler

et al. 2014

Thrombosis Research

View full text Add to dashboard Cite

Section: Recruitment Of Participantsmentioning

confidence: 99%

Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study

Geisthoff

Seyfert

Kübler

et al. 2014

Thrombosis Research

View full text Add to dashboard Cite

“…15 TXA binds more strongly than e-aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in the potency between the compounds. 15 TXA has been previously used quite successfully in joint replacement surgery and in cardiac, urological, gynecological, and thoracic surgical procedures to reduce operative blood loss. 11 , 13 , 16 -20 However, considerable complications of antifi brinolytic acid have also been documented.…”

mentioning

confidence: 98%

Does the Intraoperative Tranexamic Acid Decrease Operative Blood Loss During Posterior Spinal Fusion for Treatment of Adolescent Idiopathic Scoliosis?

Yagi

Hasegawa

Nagoshi

et al. 2012

Spine

View full text Add to dashboard Cite

Study Design. Retrospective, observational study. Objective. To assess the effi cacy and safety of tranexamic acid (TXA) in decreasing operative blood loss and the need for transfusion during posterior spinal fusion for the treatment of idiopathic scoliosis in adolescents. Summary of Background Data. Blood loss associated with spinal surgery is a common potential cause of morbidity and often requires a blood transfusion, which subjects patients to the known risks of blood transfusion including transmission of diseases. Since the 1990s, intraoperative administration of antifi brinolytics has gained popularity. This study assesses the effi cacy and safety of TXA in controlling blood loss during posterior spinal fusion for the treatment of idiopathic scoliosis in adolescents at 1 institution. Methods. A retrospective comparative analysis of 106 consecutive adolescents undergoing posterior spinal fusion procedures at 1 institution was performed. Patients were analyzed according to treatment group: controls (63) and TXA (43). There were no signifi cant differences in demographic (age, sex, and comorbidities) or surgical traits (surgical time, number of fused vertebrae, preoperative hematocrit and hemoglobin) between the 2 groups. Results. TXA group had signifi cantly less intraoperative blood loss (613 ± 195 mL) than the control group (1079 ± 421 mL; P < 0.001) as well as postoperative blood loss (155 ± 86 mL and 263 ± 105 mL, respectively; P < 0.001). TXA group received signifi cantly less blood during the surgical procedure than the control group (258 ±

show abstract

“…27,28 This allows for coagulation to occur in the absence of fibrinolysis, thus contributing to hemostasis and reduced blood loss locally at the site of injury. Because tranexamic acid is a synthetic compound, it is not associated with hypersensitivity reactions as seen with aprotinin, and it is associated with decreased cost.…”

Section: Discussionmentioning

confidence: 98%